Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05648383 |
Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or Hypertension |
UNKNOWN | NA |
| NCT04304963 |
Hypo-METRICS: Hypoglycaemia - Measurement, ThResholds and ImpaCtS |
COMPLETED | |
| NCT02845869 |
Evaluating Light Therapy for Treatment of Overuse Anterior Knee Pain |
COMPLETED | NA |
| NCT02393872 |
Feel4Diabetes-study |
UNKNOWN | NA |
| NCT01596556 |
The Effect of Smoking on Thermoregulation |
COMPLETED | NA |
| NCT01596543 |
The Effect of Partial and Complete Sleep Deprivation on Heat Tolerance |
COMPLETED | NA |
| NCT01530165 |
(Pakistan Diabetes Prevention Program PDPP) |
COMPLETED | NA |
| NCT01296100 |
DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia |
COMPLETED | NA |
| NCT00389259 |
Scopolamine Treatment for Patients With Organophosphate Poisoning |
WITHDRAWN | NA |
